Literature DB >> 25646354

Association of Oseltamivir Treatment With Virus Shedding, Illness, and Household Transmission of Influenza Viruses.

Doug H Cheung1, Tim K Tsang2, Vicky J Fang2, Jiajing Xu2, Kwok-Hung Chan3, Dennis K M Ip2, Joseph Sriyal Malik Peiris4, Gabriel M Leung2, Benjamin J Cowling2.   

Abstract

In an observational study of 582 patients with laboratory-confirmed influenza virus infections and their household contacts, we found that the initiation of oseltamivir within 24 hours was associated with shorter duration of self-reported illness symptoms (56% reduction in duration; 95% confidence interval, 41%-67%). However, we did not find any association of oseltamivir treatment with duration of viral shedding by polymerase chain reaction or with the risk of household transmission.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  acute respiratory illness; influenza; oseltamivir

Mesh：

Substances：

Year:  2015        PMID： 25646354      PMCID： PMC4866553          DOI： 10.1093/infdis/jiv058

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  14 in total

1.  Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.

Authors:  Frederick G Hayden; Robert Belshe; Catalina Villanueva; Riin Lanno; Claire Hughes; Ian Small; Regina Dutkowski; Penelope Ward; Jackie Carr
Journal:  J Infect Dis       Date:  2004-01-26       Impact factor: 5.226

2.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.

Authors:  Linda E Lévesque; James A Hanley; Abbas Kezouh; Samy Suissa
Journal:  BMJ       Date:  2010-03-12

Review 3.  Tutorial in biostatistics methods for interval-censored data.

Authors:  J C Lindsey; L M Ryan
Journal:  Stat Med       Date:  1998-01-30       Impact factor: 2.373

4.  Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials.

Authors:  Miguel A Hernán; Marc Lipsitch
Journal:  Clin Infect Dis       Date:  2011-06-15       Impact factor: 9.079

5.  Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus.

Authors:  Sophia Ng; Benjamin J Cowling; Vicky J Fang; Kwok Hung Chan; Dennis K M Ip; Calvin K Y Cheng; Timothy M Uyeki; Peter M Houck; J S Malik Peiris; Gabriel M Leung
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

6.  Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial.

Authors:  Benjamin J Cowling; Kwok-Hung Chan; Vicky J Fang; Calvin K Y Cheng; Rita O P Fung; Winnie Wai; Joey Sin; Wing Hong Seto; Raymond Yung; Daniel W S Chu; Billy C F Chiu; Paco W Y Lee; Ming Chi Chiu; Hoi Che Lee; Timothy M Uyeki; Peter M Houck; J S Malik Peiris; Gabriel M Leung
Journal:  Ann Intern Med       Date:  2009-08-03       Impact factor: 25.391

7.  Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.

Authors:  Alicia M Fry; Doli Goswami; Kamrun Nahar; Amina Tahia Sharmin; Mustafizur Rahman; Larisa Gubareva; Tasnim Azim; Joseph Bresee; Stephen P Luby; W Abdullah Brooks
Journal:  Lancet Infect Dis       Date:  2013-11-22       Impact factor: 25.071

8.  Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States.

Authors:  Simon Cauchemez; Christl A Donnelly; Carrie Reed; Azra C Ghani; Christophe Fraser; Charlotte K Kent; Lyn Finelli; Neil M Ferguson
Journal:  N Engl J Med       Date:  2009-12-31       Impact factor: 91.245

Review 9.  Regulating the adaptive immune response to respiratory virus infection.

Authors:  Thomas J Braciale; Jie Sun; Taeg S Kim
Journal:  Nat Rev Immunol       Date:  2012-03-09       Impact factor: 53.106

Review 10.  Neuraminidase inhibitors for preventing and treating influenza in adults and children.

Authors:  Tom Jefferson; Mark A Jones; Peter Doshi; Chris B Del Mar; Rokuro Hama; Matthew J Thompson; Elizabeth A Spencer; Igho Onakpoya; Kamal R Mahtani; David Nunan; Jeremy Howick; Carl J Heneghan
Journal:  Cochrane Database Syst Rev       Date:  2014-04-10
View more
  13 in total

1.  Viral Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Influenza Virus Infections in the Community.

Authors:  Dennis K M Ip; Lincoln L H Lau; Nancy H L Leung; Vicky J Fang; Kwok-Hung Chan; Daniel K W Chu; Gabriel M Leung; J S Malik Peiris; Timothy M Uyeki; Benjamin J Cowling
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

2.  Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.

Authors:  Ann Esquivel; William W Busse; Agustin Calatroni; Alkis G Togias; Kristine G Grindle; Yury A Bochkov; Rebecca S Gruchalla; Meyer Kattan; Carolyn M Kercsmar; G Khurana Hershey; Haejin Kim; Petra Lebeau; Andrew H Liu; Stanley J Szefler; Stephen J Teach; Joseph B West; Jeremy Wildfire; Jaqueline A Pongracic; James E Gern
Journal:  Am J Respir Crit Care Med       Date:  2017-10-15       Impact factor: 21.405

3.  Transmission Modeling with Regression Adjustment for Analyzing Household-based Studies of Infectious Disease: Application to Tuberculosis.

Authors:  Forrest W Crawford; Florian M Marx; Jon Zelner; Ted Cohen
Journal:  Epidemiology       Date:  2020-03       Impact factor: 4.860

4.  Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study.

Authors:  John H Beigel; Pablo Tebas; Marie-Carmelle Elie-Turenne; Ednan Bajwa; Todd E Bell; Charles B Cairns; Shmuel Shoham; Jaime G Deville; Eric Feucht; Judith Feinberg; Thomas Luke; Kanakatte Raviprakash; Janine Danko; Dorothy O'Neil; Julia A Metcalf; Karen King; Timothy H Burgess; Evgenia Aga; H Clifford Lane; Michael D Hughes; Richard T Davey
Journal:  Lancet Respir Med       Date:  2017-05-15       Impact factor: 30.700

5.  An Infant Mouse Model of Influenza Virus Transmission Demonstrates the Role of Virus-Specific Shedding, Humoral Immunity, and Sialidase Expression by Colonizing Streptococcus pneumoniae.

Authors:  Mila Brum Ortigoza; Simone B Blaser; M Ammar Zafar; Alexandria J Hammond; Jeffrey N Weiser
Journal:  mBio       Date:  2018-12-18       Impact factor: 7.867

6.  Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance.

Authors:  Rueshandra Roosenhoff; Erhard van der Vries; Anne van der Linden; Geert van Amerongen; Koert J Stittelaar; Saskia L Smits; Martin Schutten; Ron A M Fouchier
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

7.  Point-of-care molecular testing and antiviral treatment of influenza in residents of homeless shelters in Seattle, WA: study protocol for a stepped-wedge cluster-randomized controlled trial.

Authors:  Kira L Newman; Julia H Rogers; Denise McCulloch; Naomi Wilcox; Janet A Englund; Michael Boeckh; Timothy M Uyeki; Michael L Jackson; Lea Starita; James P Hughes; Helen Y Chu
Journal:  Trials       Date:  2020-11-23       Impact factor: 2.279

Review 8.  Household Transmission of Influenza Virus.

Authors:  Tim K Tsang; Lincoln L H Lau; Simon Cauchemez; Benjamin J Cowling
Journal:  Trends Microbiol       Date:  2015-11-21       Impact factor: 17.079

9.  The reachability of contagion in temporal contact networks: how disease latency can exploit the rhythm of human behavior.

Authors:  Ewan Colman; Kristen Spies; Shweta Bansal
Journal:  BMC Infect Dis       Date:  2018-05-15       Impact factor: 3.090

10.  Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission.

Authors:  Leo Yi Yang Lee; Jie Zhou; Rebecca Frise; Daniel H Goldhill; Paulina Koszalka; Edin J Mifsud; Kaoru Baba; Takahiro Noda; Yoshinori Ando; Kenji Sato; Aoe-Ishikawa Yuki; Takao Shishido; Takeki Uehara; Steffen Wildum; Elke Zwanziger; Neil Collinson; Klaus Kuhlbusch; Barry Clinch; Aeron C Hurt; Wendy S Barclay
Journal:  PLoS Pathog       Date:  2020-04-15       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.